Sign in
LMNL Stock Price, Chart, Stats & News
Liminal BioSciences Inc.
Save
27.62M
Market cap
–
Current P/E
–
Forward P/E
LMNL chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -8223.19% |
Pretax margin | -7341.90% |
Net margin | -7210.97% |
Effective tax rate | 1.78% |
ROA | -57.31% |
ROE | -73.35% |
D/E | 0.04x |
Interest coverage ratio | -30.59x |
LMNL valuation
P/E | – |
P/S | 95.64x |
P/B | 0.03x |
P/CF | -0.03x |
P/FCF | -1.20x |
P/OCF | -0.03x |
PEG | -0.00x |
EV multiple | -2.32x |
About
Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials.
Similar securities
Based on sector and market capitalization
Report issue